24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Nemolizumab provided rapid and sustained itch relief with gradual lesion improvement in real-world PN. Early pruritus response may predict long-term efficacy, while adverse events affect treatment persistence.

Authors

Yoshihito Mima (ORCID: https://orcid.org/0009-0000-4832-1899)
Masako Yamamoto
Ken Iozumi

Institutions

Tokyo Metropolitan Police Hospital (JP)

Publication Details

Journal: Journal of Dermatological Treatment
Published: 2026-02-03
DOI: https://doi.org/10.1080/09546634.2026.2624225
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Yoshihito Mima, Masako Yamamoto, Ken Iozumi

Feb 3, 2026

Journal of Dermatological Treatment

Dermatology and Skin Diseases

article

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Yoshihito Mima, Masako Yamamoto, Ken Iozumi

February 3, 2026article en

Abstract

Journal of Dermatological TreatmentVol. 37(1)

Tokyo Metropolitan Police Hospital (JP)

Openalex Percentile: Top 69%

Dermatology and Skin Diseases

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

24-week real world outcomes of nemolizumab in patients with prurigo nodularis — Yoshihito Mima, Masako Yamamoto, et al. · Journal of Dermatological Treatment (2026) | TGRS Research Map | TGRS